Natco Pharma received in-principle approval from the Bombay Stock Exchange and National Stock Exchange on September 21, 2026, for its proposed rights issue of fully paid-up equity shares.

The approvals mark a procedural milestone for the capital raise. The company confirmed receipt of the nod from both exchanges in a filing submitted to their respective listing departments.

Regulatory Filings

The company notified the Corporate Relationship Department of BSE Ltd and the Manager – Listing at NSE Ltd regarding the development. The intimation was signed by Ch. Venkat Ramesh, Company Secretary & Compliance Officer, on September 21, 2026.

Document Availability

Copies of the in-principle approval letters are available on the company’s investor relations website. Stakeholders can access the documents via the dedicated rights issue section hosted by Natco Pharma.

Natco Pharma 's board approved a ₹1,300 crore rights issue of equity shares to existing shareholders on September 9, 2026. The draft letter of offer was also approved.

Rights issue details

The company specified that the fundraising will be executed through a rights issue, replacing the earlier broader mandate for equity or other securities. The shares will have a face value of ₹2 each. The final number of shares and the issue price will be determined later, along with the record date for eligibility.

A Fund-Raising Committee comprising Chairman V.C. Nannapaneni, Rajeev Nannapaneni, and P.S.R.K. Prasad was constituted to oversee the process.

Impact on demerger scheme

The rights issue is expected to alter the company's capital structure and shareholding pattern. Consequently, Natco Pharma must revise its pending Scheme of Arrangement involving the demerger of Natco Crop Health Sciences Limited.

The company has received observation letters from stock exchanges regarding the original scheme but has not yet filed it with the National Company Law Tribunal. The board decided to update the scheme post-completion of the rights issue to maintain the originally proposed share swap ratio. Revised filings will be submitted to the exchanges after the capital raise is complete.